Inhibition of CD9 expression reduces the metastatic capacity of human hepatocellular carcinoma cell line MHCC97-H

Lin,Qing; Peng,Shifang; Yang, Yixuan

doi:10.3892/ijo.2018.4381

Inhibition of CD9 expression reduces the metastatic capacity of human hepatocellular carcinoma cell line MHCC97-H

Authors:
- Qing Lin
- Shifang Peng
- Yixuan Yang
View Affiliations

Affiliations: Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China, Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: April 26, 2018 https://doi.org/10.3892/ijo.2018.4381
Pages: 266-274

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis is a characteristic of malignant tumors and may be a fatal clinical factor for many patients with cancer. Hepatocellular carcinoma (HCC) cells are highly metastatic; the mechanism of metastasis is complicated and may be influenced by a number of factors. Membrane proteins may block receptors or inhibit important enzymes, thus inhibiting tumor progression, and may be potential therapeutic targets for tumor prognosis and treatment. The present study aimed to use proteomics to analyze the dynamic changes of membrane proteins in HCC cells, to improve our understanding of membrane protein functions and to clarify the important components of the mechanisms of HCC metastasis. The present study used the highly metastatic MHCC97-H and the lowly metastatic MHCC97-L HCC cell lines, and the isobaric tags for relative and absolute quantitation (iTRAQ) approach was used for high-throughput screening of metastasis-related membrane proteins. A total of 22 membrane proteins were identified as differentially expressed between the MHCC97-H and MHCC97-L cell lines; these results were verified by reverse transcription-quantitative polymerase chain reaction and western blotting. A number of the identified proteins were revealed to be related to tumor metastasis, including the tetraspan in transmembrane protein CD9. CD9 was demonstrated to be highly expressed in MHCC97-H cells compared with MHCC97-L cells. The functional role of CD9 was characterized by inhibiting its expression using a small interfering RNAs, which demonstrated that reduced CD9 expression inhibited cell migration and metastasis, as determined by wound-healing and invasion assays. Results from the present study demonstrated that CD9 was highly expressed in the highly metastatic HCC cells and promoted HCC cell migration. This protein may be a novel target for regulating the invasive phenotype in HCC.

View Figures

View References

1	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
3	El-Serag HB and Kanwal F: Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go? Hepatology. 60:1767–1775. 2014. View Article : Google Scholar : PubMed/NCBI
4	Bruix J and Sherman M; American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
5	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
6	Josic D, Clifton JG, Kovac S and Hixson DC: Membrane proteins as diagnostic biomarkers and targets for new therapies. Curr Opin Mol Ther. 10:116–123. 2008.PubMed/NCBI
7	Boonstra MC, de Geus SW, Prevoo HA, Hawinkels LJ, van de Velde CJ, Kuppen PJ, Vahrmeijer AL and Sier CF: Selecting targets for tumor imaging: An overview of cancer-associated membrane proteins. Biomark Cancer. 8:119–133. 2016.PubMed/NCBI
8	Mamede AC, Laranjo M, Carvalho MJ, Abrantes AM, Pires AS, Brito AF, Moura P, Maia CJ and Botelho MF: Effect of amniotic membrane proteins in human cancer cell lines: An exploratory study. J Membr Biol. 247:357–360. 2014. View Article : Google Scholar : PubMed/NCBI
9	Rucevic M, Hixson D and Josic D: Mammalian plasma membrane proteins as potential biomarkers and drug targets. Electrophoresis. 32:1549–1564. 2011. View Article : Google Scholar : PubMed/NCBI
10	Li SY, Yu B, An P, Liang ZJ, Yuan SJ and Cai HY: Effects of cell membrane phospholipid level and protein kinase C isoenzyme expression on hepatic metastasis of colorectal carcinoma. Hepatobiliary Pancreat Dis Int. 3:411–416. 2004.PubMed/NCBI
11	Sun GG, Wang YD, Cui DW, Cheng YJ and Hu WN: Epithelial membrane protein 1 negatively regulates cell growth and metastasis in colorectal carcinoma. World J Gastroenterol. 20:4001–4010. 2014. View Article : Google Scholar : PubMed/NCBI
12	Agarwal AK, Srinivasan N, Godbole R, More SK, Budnar S, Gude RP and Kalraiya RD: Role of tumor cell surface lysosome-associated membrane protein-1 (LAMP1) and its associated carbohydrates in lung metastasis. J Cancer Res Clin Oncol. 141:1563–1574. 2015. View Article : Google Scholar : PubMed/NCBI
13	Lee TY, Chang HH, Kuo JJ and Shen JJ: Changes of hepatic proteome in bile duct ligated rats with hepatic fibrosis following treatment with Yin-Chen-Hao-Tang. Int J Mol Med. 23:477–484. 2009. View Article : Google Scholar : PubMed/NCBI
14	Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, et al: Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 3:1154–1169. 2004. View Article : Google Scholar : PubMed/NCBI
15	Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, Chen J, Gao DM and Bao WH: Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol. 7:630–636. 2001. View Article : Google Scholar
16	Wang C, Zhu ZM, Liu CL, He XJ, Zhang HY and Dong JH: Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells. Mol Med Rep. 11:4101–4108. 2015. View Article : Google Scholar : PubMed/NCBI
17	Zou YH, Li XD, Zhang QH and Liu DZ: RACK1 silencing induces cell apoptosis and inhibits cell proliferation in hepatocellular carcinoma MHCC97-H cells. Pathol Oncol Res. 24:101–107. 2018. View Article : Google Scholar
18	Tian M, Cheng H, Wang Z, Su N, Liu Z, Sun C, Zhen B, Hong X, Xue Y and Xu P: Phosphoproteomic analysis of the highly-metastatic hepatocellular carcinoma cell line, MHCC97-H. Int J Mol Sci. 16:4209–4225. 2015. View Article : Google Scholar : PubMed/NCBI
19	Sun H and Liu GT: Inhibitory effect of anti-hepatitis drug bicyclol on invasion of human hepatocellular carcinoma MHCC97-H cells with high metastasis potential and its relative mechanisms. J Asian Nat Prod Res. 11:576–583. 2009. View Article : Google Scholar
20	Yang Y, Toy W, Choong LY, Hou P, Ashktorab H, Smoot DT, Yeoh KG and Lim YP: Discovery of SLC3A2 cell membrane protein as a potential gastric cancer biomarker: Implications in molecular imaging. J Proteome Res. 11:5736–5747. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wang LN, Tong SW, Hu HD, Ye F, Li SL, Ren H, Zhang DZ, Xiang R and Yang YX: Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach. J Cell Biochem. 113:3762–3772. 2012. View Article : Google Scholar : PubMed/NCBI
22	She S, Xiang Y, Yang M, Ding X, Liu X, Ma L, Liu Q, Liu B, Lu Z, Li S, et al: C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma. Int J Oncol. 47:543–554. 2015. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
24	Bledi Y, Inberg A and Linial M: PROCEED: A proteomic method for analysing plasma membrane proteins in living mammalian cells. Brief Funct Genomics Proteomics. 2:254–265. 2003. View Article : Google Scholar
25	Josic D and Clifton JG: Mammalian plasma membrane proteomics. Proteomics. 7:3010–3029. 2007. View Article : Google Scholar : PubMed/NCBI
26	Zhang H, Tian B, Yu H, Yao H and Gao Z: LAPTM4B-35 protein as a potential therapeutic target in gastric cancer. Tumour Biol. 35:12737–12742. 2014. View Article : Google Scholar : PubMed/NCBI
27	Yoshizaki T, Kondo S, Endo K, Nakanishi Y, Aga M, Kobayashi E, Hirai N, Sugimoto H, Hatano M, Ueno T, et al: Modulation of the tumor microenvironment by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. Cancer Sci. 109:272–278. 2018. View Article : Google Scholar
28	Xue Q, Zhou Y, Wan C, Lv L, Chen B, Cao X, Ju G, Huang Y, Ni R and Mao G: Epithelial membrane protein 3 is frequently shown as promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. Exp Mol Pathol. 95:313–318. 2013. View Article : Google Scholar : PubMed/NCBI
29	Liang S, Xu Z, Xu X, Zhao X, Huang C and Wei Y: Quantitative proteomics for cancer biomarker discovery. Comb Chem High Throughput Screen. 15:221–231. 2012. View Article : Google Scholar : PubMed/NCBI
30	Tian J, Tang Z and Ye S: Establishment of a human hepatocellular carcinoma (HCC) cell line with high metastatic potential (MHCC97) and its biological characteristics. Zhonghua Zhong Liu Za Zhi. 20:405–407. 1998.In Chinese.
31	Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J and Xue Q: New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer. 81:814–821. 1999. View Article : Google Scholar : PubMed/NCBI
32	Chen B, Wang J, Dai D, Zhou Q, Guo X, Tian Z, Huang X, Yang L, Tang H and Xie X: AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. J Exp Clin Cancer Res. 36:652017. View Article : Google Scholar : PubMed/NCBI
33	Hoe SL, Tan LP, Abdul Aziz N, Liew K, Teow SY, Abdul Razak FR, Chin YM, Mohamed Shahrehan NA, Chu TL, Mohd Kornain NK, et al: CD24, CD44 and EpCAM enrich for tumour-initiating cells in a newly established patient-derived xenograft of nasopharyngeal carcinoma. Sci Rep. 7:123722017. View Article : Google Scholar : PubMed/NCBI
34	Qin Q, Wei F, Zhang J and Li B: miR-134 suppresses the migration and invasion of non small cell lung cancer by targeting ITGB1. Oncol Rep. 37:823–830. 2017. View Article : Google Scholar : PubMed/NCBI
35	Yáñez-Mó M, Barreiro O, Gordon-Alonso M, Sala-Valdés M and Sánchez-Madrid F: Tetraspanin-enriched microdomains: A functional unit in cell plasma membranes. Trends Cell Biol. 19:434–446. 2009. View Article : Google Scholar : PubMed/NCBI
36	Zöller M: Tetraspanins: Push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 9:40–55. 2009. View Article : Google Scholar
37	Hemler ME: Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 19:397–422. 2003. View Article : Google Scholar : PubMed/NCBI
38	Zijlstra A, Lewis J, Degryse B, Stuhlmann H and Quigley JP: The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell. 13:221–234. 2008. View Article : Google Scholar : PubMed/NCBI
39	Schröder HM, Hoffmann SC, Hecker M, Korff T and Ludwig T: The tetraspanin network modulates MT1-MMP cell surface trafficking. Int J Biochem Cell Biol. 45:1133–1144. 2013. View Article : Google Scholar : PubMed/NCBI
40	Boucheix C and Rubinstein E: Tetraspanins. Cell Mol Life Sci. 58:1189–1205. 2001. View Article : Google Scholar : PubMed/NCBI
41	Boucheix C, Benoit P, Frachet P, Billard M, Worthington RE, Gagnon J and Uzan G: Molecular cloning of the CD9 antigen. A new family of cell surface proteins. J Biol Chem. 266:117–122. 1991.PubMed/NCBI
42	Lanza F, Wolf D, Fox CF, Kieffer N, Seyer JM, Fried VA, Coughlin SR, Phillips DR and Jennings LK: cDNA cloning and expression of platelet p24/CD9. Evidence for a new family of multiple membrane-spanning proteins. J Biol Chem. 266:10638–10645. 1991.PubMed/NCBI
43	Maecker HT, Todd SC and Levy S: The tetraspanin superfamily: Molecular facilitators. FASEB J. 11:428–442. 1997. View Article : Google Scholar : PubMed/NCBI
44	Miyake M, Nakano K, Itoi SI, Koh T and Taki T: Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res. 56:1244–1249. 1996.PubMed/NCBI
45	Copeland BT, Bowman MJ, Boucheix C and Ashman LK: Knockout of the tetraspanin Cd9 in the TRAMP model of de novo prostate cancer increases spontaneous metastases in an organ-specific manner. Int J Cancer. 133:1803–1812. 2013. View Article : Google Scholar : PubMed/NCBI
46	Hashida H, Takabayashi A, Tokuhara T, Taki T, Kondo K, Kohno N, Yamaoka Y and Miyake M: Integrin α3 expression as a prognostic factor in colon cancer: Association with MRP-1/CD9 and KAI1/CD82. Int J Cancer. 97:518–525. 2002. View Article : Google Scholar : PubMed/NCBI
47	Higashiyama M, Taki T, Ieki Y, Adachi M, Huang CL, Koh T, Kodama K, Doi O and Miyake M: Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res. 55:6040–6044. 1995.PubMed/NCBI
48	Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, Beckers A, de Preter K, Decock A, Patil N, et al: MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget. 7:66344–66359. 2016. View Article : Google Scholar : PubMed/NCBI
49	Houle CD, Ding XY, Foley JF, Afshari CA, Barrett JC and Davis BJ: Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression. Gynecol Oncol. 86:69–78. 2002. View Article : Google Scholar : PubMed/NCBI
50	Sauer G, Windisch J, Kurzeder C, Heilmann V, Kreienberg R and Deissler H: Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res. 9:6426–6431. 2003.PubMed/NCBI
51	Wang JC, Bégin LR, Bérubé NG, Chevalier S, Aprikian AG, Gourdeau H and Chevrette M: Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clin Cancer Res. 13:2354–2361. 2007. View Article : Google Scholar : PubMed/NCBI
52	Herr MJ, Kotha J, Hagedorn N, Smith B and Jennings LK: Tetraspanin CD9 promotes the invasive phenotype of human fibrosarcoma cells via upregulation of matrix metalloproteinase-9. PLoS One. 8:e677662013. View Article : Google Scholar : PubMed/NCBI
53	Zheng R, Yano S, Zhang H, Nakataki E, Tachibana I, Kawase I, Hayashi S and Sone S: CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice. Oncol Res. 15:365–372. 2005. View Article : Google Scholar
54	Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
55	Sho M, Adachi M, Taki T, Hashida H, Konishi T, Huang CL, Ikeda N, Nakajima Y, Kanehiro H, Hisanaga M, et al: Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer. 79:509–516. 1998. View Article : Google Scholar : PubMed/NCBI
56	Mori M, Mimori K, Shiraishi T, Haraguchi M, Ueo H, Barnard GF and Akiyoshi T: Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res. 4:1507–1510. 1998.PubMed/NCBI